Cholesterol-lowering properties of oat β-glucan and the promotion of cardiovascular health: Did health canada make the right call?

Applied Physiology, Nutrition and Metabolism

Volumn 40, Issue 6, 2015, Pages 535-542

  Nwachukwu, Ifeanyi D ^a   Devassy, Jessay G ^a   Aluko, Rotimi E ^a,b   Jones, Peter J H ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Avena sativa; Claim validity; Functional food; HDL; Health claim; Hypercholesterolemia; Hyperlipidemia; LDL; Soluble fibre; Viscosity

Indexed keywords

BETA GLUCAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADMINISTRATION AND DOSAGE; AVENA; BLOOD; CANADA; CARDIOVASCULAR SYSTEM; CHEMISTRY; CORONARY DISEASE; DIETARY FIBER; DIETARY REFERENCE INTAKE; DRUG EFFECTS; HEALTH PROMOTION; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

AVENA; BETA-GLUCANS; CANADA; CARDIOVASCULAR SYSTEM; CHOLESTEROL, HDL; CORONARY DISEASE; DIETARY FIBER; HEALTH PROMOTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMMENDED DIETARY ALLOWANCES; RISK FACTORS; TRIGLYCERIDES;

EID: 84930149100     PISSN: 17155312     EISSN: 17155320     Source Type: Journal    
DOI: 10.1139/apnm-2014-0410     Document Type: Review

References (47)

1. Andersson, M., Ellegard, L., and Andersson, H. 2002. Oat bran stimulates bile acid synthesis within 8 h as measured by 7 alpha-hydroxy-4-cholesten-3-one. Am. J. Clin. Nutr. 76(5): 1111-1116.PMID:12399287.
2. Beck, E.J., Tapsell, L.C., Batterham, M.J., Tosh, S.M., and Huang, X.F. 2010. Oat β-glucan supplementation does not enhance the effectiveness of an energyrestricted diet in overweight women. Br. J. Nutr. 103(8): 1212-1222. doi:10.1017/S0007114509992856.PMID:19930764.
3. Butt, M.S., Tahir-Nadeem, M., Khan, M.K.I., Shabir, R., and Butt, M.S. 2008. Oat: unique among the cereals. Eur. J. Nutr. 47(2): 68-79. doi:10.1007/s00394-008-0698-7.PMID:18301937.
4. CFIA. 2013. Guide to food labelling and advertising. [Online.] Available from http://www.inspection.gc.ca/english/fssa/labeti/guide/toce.shtml. [Accessed 24 June 2014.]
5. Charlton, K.E., Tapsell, L.C., Batterham, M.J., O’Shea, J., Thorne, R., Beck, E., and Tosh, S.M. 2012. Effect of 6 weeks’ consumption of β-glucan-rich oat products on cholesterol levels in mildly hypercholesterolaemic overweight adults. Br. J. Nutr. 107(7): 1037-1047. doi:10.1017/S0007114511003850.PMID:21810288.
6. Chen, J., and Huang, X.F. 2009. The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. J. Clin. Lipidol. 3(3): 154-158. doi:10.1016/j.jacl.2009.04.054.PMID:21291810.
7. Cohen, J.C. 1999. Contribution of cholesterol 7β-hydroxylase to the regulation of lipoprotein metabolism. Curr. Opin. Lipidol. 10(4): 303-307. doi:10.1097/00041433-199908000-00003.PMID:10482132.
8. Cugnet-Anceau, C., Nazare, J.A., Biorklund, M., Le Coquil, E., Sassolas, A., Sothier, M., et al. 2010. A controlled study of consumption of β-glucanenriched soups for 2 months by type 2 diabetic free-living subjects. Br. J. Nutr. 103(3): 422-428. doi:10.1017/S0007114509991875.PMID:19781120.
9. Dickson, M., and Gagnon, J.P. 2004. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discov. 3(5): 417-429. doi:10.1038/nrd1382.PMID:15136789.
10. FSANZ. 2013. Standard 1.2.7 - nutrition, health and related claims. [Online.] Available from http://www.comlaw.gov.au/Details/F2013L00054. [Accessed 24 June 2014.]
11. Gorog, D.A. 2010. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J. Am. Coll. Cardiol. 55(24): 2701-2709. doi:10.1016/j.jacc.2009.11.095.PMID:20538163.
12. Haggard, L., Andersson, M., and Punga, A.R. 2013. β-glucans reduce LDL cholesterol in patients with myasthenia gravis. Eur. J. Clin. Nutr. 67(2): 226-227. doi:10.1038/ejcn.2012.191.PMID:23187951.
13. Health Canada. 2009a. Managing health claims for foods in Canada: towards a modernized framework. [Online.] Available fromhttp://www.hc-sc.gc.ca/fn-an/consult/_man-gest_health_claims-allegations_sante/index-eng.php. [Accessed 24 June 2014.]
14. Health Canada. 2009b. Guidance Document for Preparing a Submission for Food Health Claims. [Online.] Available from http://www.hc-sc.gc.ca/fn-an/legislation/guide-ld/health-claims_guidance-orientation_allegations-santeeng. php#a5-1-1. [Accessed 20 May 2014.]
15. Health Canada. 2010. Oat products and blood cholesterol lowering. [Online.] Available from http://www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/ assess-evalu/oat-avoine-eng.php. [Accessed 20 May 2014.]
16. Health Canada. 2012. Health claims. [Online.] Available from http://www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/index-eng.php. [Accessed 24 June 2014.]
17. Hu, F.B. 2003. Plant-based foods and prevention of cardiovascular disease: an overview. Am. J. Clin. Nutr. 78(3 Suppl.): 544S-551S.PMID:12936948.
18. Hu, F.B., and Willett, W.C. 2002. Optimal diets for prevention of coronary heart disease. J. Am. Med. Assoc. 288(20): 2569-2578. doi:10.1001/jama.288.20.2569.PMID:12444864.
19. Ibrugger, S., Kristensen, M., Poulsen, M.W., Mikkelsen, M.S., Ejsing, J., Jespersen, B.M., et al. 2013. Extracted oat and barley β-glucans do not affect cholesterol metabolism in young healthy adults. J. Nutr. 143(10): 1579-1585. doi:10.3945/jn.112.173054.PMID:23946347.
20. Jenkins, D.J.A., Wolever, T.M.S., Rao, A.V., Hegele, R.A., Mitchell, S.J., Ransom, T.P.P., et al. 1993. Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N. Engl. J. Med. 329(1): 21-26. doi:10.1056/NEJM199307013290104.PMID:8389421.
21. Jew, S., Vanstone, C.A., Antoine, J.M., and Jones, P.J.H. 2008. Generic and product-specific health claim processes for functional foods across global jurisdictions. J. Nutr. 138(6): 1228S-1236S.PMID:18492862.
22. Kirby, R.W., Anderson, J.W., Sieling, B., Rees, E.D., Chen, W.J., Miller, R.E., and Kay, R.M. 1981. Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men. Am. J. Clin. Nutr. 34(5): 824-829.PMID:6263072.
23. Kristensen, M., and Bugel, S. 2011. A diet rich in oat bran improves blood lipids and hemostatic factors, and reduces apparent energy digestibility in young healthy volunteers. Eur. J. Clin. Nutr. 65(9): 1053-1058. doi:10.1038/ejcn.2011.102.PMID:21654701.
24. L’Abbe, M.R., Dumais, L., Chao, E., and Junkins, B. 2008. Health claims on foods in Canada. J. Nutr. 138(6): 1221S-1227S.PMID:18492861.
25. Lawes, C.M., Hoorn, S.V., and Rodgers, A.; International Society of Hypertension. 2008. Global burden of blood-pressure-related disease, 2001. Lancet, 371(9623): 1513-1518. doi:10.1016/S0140-6736(08)60655-8.PMID:18456100.
26. Lefevre, M., Kris-Etherton, P.M., Zhao, G., and Tracy, R.P. 2004. Dietary fatty acids, hemostasis, and cardiovascular disease risk. J. Am. Diet. Assoc. 104(3): 410-419. doi:10.1016/j.jada.2003.12.022.PMID:14993864.
27. Lia, A., Hallmans, G., Sandberg, A.S., Sundberg, B., Aman, P., and Andersson, H. 1995. Oat _-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Am. J. Clin. Nutr. 62(6): 1245-1251.PMID:7491888.
28. Liatis, S., Tsapogas, P., Chala, E., Dimosthenopoulos, C., Kyriakopoulos, K., Kapantais, E., and Katsilambros, N. 2009. The consumption of bread enriched with betaglucan reduces LDL-cholesterol and improves insulin resistance in patients with type 2 diabetes. Diabetes Metab. 35(2): 115-120. doi:10.1016/j.diabet.2008.09.004.PMID:19230737.
29. Maki, K.C., Beiseigel, J.M., Jonnalagadda, S.S., Gugger, C.K., Reeves, M.S., Farmer, M.V., et al. 2010. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J. Am. Diet. Assoc. 110(2): 205-214. doi:10.1016/j.jada.2009.10.037.PMID:20102847.
30. Marlett, J.A., Hosig, K.B., Vollendorf, N.W., Shinnick, F.L., Haack, V.S., and Story, J.A. 1994. Mechanism of serum cholesterol reduction by oat bran. Hepatology, 20(6): 1450-1457. doi:10.1002/hep.1840200612.PMID:7982644.
31. Maron, B.J., Araujo, C.G.S., Thompson, P.D., Fletcher, G.F., Bayes de Luna, A., Fleg, J.L., et al. 2001. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation, 103(2): 327-334. doi:10.1161/01.CIR.103.2.327.PMID:11208698.
32. Miettinen, T.A. 1979. Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. J. Clin. Invest. 64(5): 1485-1493. doi:10.1172/JCI109607.PMID:387820.
33. Orszag, P.R., and Ellis, P. 2007. Addressing rising health care costs - a view from the congressional budget office. N. Engl. J. Med. 357(19): 1885-1887. doi:10.1056/NEJMp078191.PMID:17989379.
34. Othman R.A., Moghadasian M.H., and Jones P.J.H. 2011. Cholesterol-lowering effects of oat β-glucan. Nutr. Rev. 69(6): 299-309. doi:10.1111/j.1753-4887.2011.00401.x.PMID:21631511.
35. Pagidipati, N.J., and Gaziano, T.A. 2013. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation, 127(6): 749-756. doi:10.1161/CIRCULATIONAHA.112.128413.PMID: 23401116.
36. Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž, Verschuren, M., et al.; European Association for Cardiovascular Prevention & Rehabilitation, ESC Committee for Practice Guidelines. 2012. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 33(13): 1635-1701. doi:10.1093/eurheartj/ehs092.PMID:22555213.
37. Queenan, K.M., Stewart, M.L., Smith, K.N., Thomas, W., Fulcher, R.G., and Slavin, J.L. 2007. Concentrated oat β-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr. J. 6: 6. doi:10.1186/1475-2891-6-6.PMID:17386092.
38. Reyna-Villasmil, N., Bermudez-Pirela, V., Mengual-Moreno, E., Arias, N., Cano-Ponce, C., Leal-Gonzalez, E., et al. 2007. Oat-derived β-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia. Am. J. Ther. 14(2): 203-212. doi:10.1097/01.pap.0000249917.96509.e7.PMID:17414591.
39. Rondanelli, M., Opizzi, A., Monteferrario, F., Klersy, C., Cazzola, R., and Cestaro, B. 2011. Beta-glucan- or rice bran-enriched foods: a comparative crossover clinical trial on lipidic pattern in mildly hypercholesterolemic men. Eur. J. Clin. Nutr. 65(7): 864-871. doi:10.1038/ejcn.2011.48.PMID:21505506.
40. Schulze, M.B., Manson, J.E., Ludwig, D.S., Colditz, G.A., Stampfer, M.J., Willett, W.C., et al. 2004. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. J. Am. Med. Assoc. 292(8): 927-934. doi:10.1001/jama.292.8.927.PMID:15328324.
41. Smith, S.C., Jr., Collins, A., Ferrari, R., Holmes, D.R., Jr., Logstrup, S., McGhie, D.V., et al.; World Heart Federation, American Heart Association, American College of Cardiology Foundation, European Heart Network, European Society of Cardiology. 2012. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). J. Am. Coll. Cardiol. 60(22): 2343-2348. doi:10.1016/j.jacc.2012.08.962.PMID:22995536.
42. Theuwissen, E., and Mensink, R.P. 2007. Simultaneous intake of β-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. J. Nutr. 137(3): 583-588.PMID:17311944.
43. WHO. 2014. The top 10 causes of death. [Online.] Available from http://www.who.int/mediacentre/factsheets/fs310/en/. [Accessed 30 August 2014.]
44. Willett, W.C. 2002. Balancing life-style and genomics research for disease prevention. Science, 296(5568): 695-698. doi:10.1126/science.1071055.PMID:11976443.
45. Wolever, T.M.S., Tosh, S.M., Gibbs, A.L., Brand-Miller, J., Duncan, A.M., Hart, V., et al. 2010. Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am. J. Clin. Nutr. 92(4): 723-732. doi:10.3945/ajcn.2010.29174.PMID:20660224.
46. Wood, P.J., Beer, M.U., and Butler, G. 2000. Evaluation of role of concentration and molecular weight of oat β-glucan in determining effect of viscosity on plasma glucose and insulin following an oral glucose load. Br. J. Nutr. 84(1): 19-23.PMID:10961156.
47. Zhang, J., Li, L., Song, P., Wang, C., Man, Q., Meng, L., et al. 2012. Randomized controlled trial of oatmeal consumption versus noodle consumption on blood lipids of urban Chinese adults with hypercholesterolemia. Nutr. J. 11: 54. doi:10.1186/1475-2891-11-54.PMID:22866937.